ArticleOncotarget2016
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- MicroRNAs in Esophageal Cancer: Implications for Diagnosis, Progression, Prognosis and Chemoresistance.International journal of molecular sciences · 2026Review
- Nonendoscopic Screening for Barrett's Esophagus: Current Methods, Evidence, and Future Directions.Gastro hep advances · 2026Review
- Advances in Screening for Barrett Esophagus and Esophageal Adenocarcinoma.Mayo Clinic proceedings · 2024Review
- New Techniques to Screen for Barrett Esophagus.Gastroenterology & hepatology · 2023Article
- Epigenetic Alterations from Barrett's Esophagus to Esophageal Adenocarcinoma.International journal of molecular sciences · 2023Review
- Expanding beyond endoscopy: A review of non-invasive modalities in Barrett's esophagus screening and surveillance.World journal of gastroenterology · 2022Review
- Article
- Comprehensive RNA dataset of tissue and plasma from patients with esophageal cancer or precursor lesions.Scientific data · 2022Article
- Screening for Barrett's Oesophagus: Are We Ready for it?Current treatment options in gastroenterology · 2021Review
- Article
- Extracellular miRNAs for the Management of Barrett's Esophagus and Esophageal Adenocarcinoma: A Systematic Review.Journal of clinical medicine · 2020Review
- Article
- Circulating exosomal miRNAs as potential biomarkers for Barrett's esophagus and esophageal adenocarcinoma.World journal of gastroenterology · 2020Review
- Novel Screening Alternatives for Barrett Esophagus.Gastroenterology & hepatology · 2020Article
- Novel Screening Tests for Barrett's Esophagus.Current gastroenterology reports · 2019Review
- Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1.Journal of oncology · 2019Article
- Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.Updates in surgery · 2018Review
- Screening for Barrett's Esophagus: Are New High-Volume Methods Feasible?Digestive diseases and sciences · 2018Review
- A Three-MicroRNA Signature as a Potential Biomarker for the Early Detection of Oral Cancer.International journal of molecular sciences · 2018Article
- Identification of key pathways and genes in Barrett's esophagus using integrated bioinformatics methods.Molecular medicine reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic changes involved in the metaplastic progression from squamous esophageal mucosa toward Barrett's metaplasia and adenocarcinoma are almost unknown. Several evidences suggest that some miRNAs are differentially expressed in Barrett's esophagus (BE) and esophageal adenocarcinoma. Among these, miR-143, miR-145, miR-194, miR-203, miR-205, miR-215 appear to have a key role in metaplasia and neoplastic progression. The aim of this study was to analyze deregulated miRNAs in serum and esophageal mucosal tissue biopsies to identify new biomarkers that could be associated with different stages of esophageal disease. Esophageal mucosal tissue biopsies and blood samples were collected and analyzed for BE diagnosis. Quantitative Real-time PCR was used to compare miRNA expression levels in serum and 60 disease/normal-paired tissues from 30 patients diagnosed with esophagitis, columnar-lined esophagus (CLO) or BE. MiRNA expression analysis showed that miR-143, miR-145, miR-194 and miR-215 levels were significantly higher, while miR-203 and miR-205 were lower in BE tissues compared with their corresponding normal tissues. Esophageal mucosa analysis of patients with CLO and esophagitis showed that these miRNAs were similarly deregulated but to a lesser extent keeping the same trend and CLO appeared as intermediate step between esophagitis and BE. Analysis on circulating miRNA levels confirmed that miR-194 and miR-215 were significantly upregulated in both BE and CLO compared to esophagitis, while miR-143 was significantly upregulated only in the Barrett group. These findings suggest that miRNAs may be involved in neoplastic/metaplastic progression and miRNA analysis might be useful for progression risk prediction as well as for monitoring of BE/CLO patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.